Publications by authors named "Arild Opheim"

Claim this Profile
H
High induction rate onto extended-release naltrexone for people with opioid use disorder: experiences from a Norwegian naturalistic study.
Jon Mordal, Farid Juya, Line Holtan, John-Kåre Vederhus, Arild Opheim

Addict Sci Clin Pract· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of relapse to non-opioid addictive substances among opioid dependent patients treated with an opioid receptor antagonist or a partial agonist: A randomized clinical trial.
Arild Opheim, Jūratė Šaltytė Benth, Kristin Klemmetsby Solli, Pia S Kloster, Lars Thore Fadnes

Contemp Clin Trials· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Predictive Value of Degree of Preference for Extended-Release Naltrexone for Treatment Adherence, Opioid Use, and Relapse.
Zhanna Gaulen, Ida Halvorsen Brenna, Lars Thore Fadnes, Jūratė Šaltytė Benth, Kristin K Solli, Arild Opheim

Eur Addict Res· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of Relapse Among Opioid-Dependent Patients Treated With Extended-Release Naltrexone or Buprenorphine-Naloxone: A Randomized Clinical Trial.
Arild Opheim, Zhanna Gaulen, Kristin Klemmetsby Solli, Zill-E-Huma Latif, Lars T Fadnes

Am J Addict· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adapting treatment length to opioid-dependent individuals' needs and preferences: A 2-year follow-up to a 1-year study of extended-release naltrexone.
Kristin Klemmetsby Solli, Arild Opheim, Zill-E-Huma Latif, Peter Krajci, Jūratė Šaltytė Benth

Addiction· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Availability of Extended-Release Naltrexone May Increase the Number of Opioid-Dependent Individuals in Treatment: Extension of a Randomized Clinical Trial.
Kristin Klemmetsby Solli, Nikolaj Kunoe, Zill-E-Huma Latif, Kamni Sharma-Haase, Arild Opheim

Eur Addict Res· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anxiety, Depression, and Insomnia Among Adults With Opioid Dependence Treated With Extended-Release Naltrexone vs Buprenorphine-Naloxone: A Randomized Clinical Trial and Follow-up Study.
Zill-E-Huma Latif, Jurate Šaltyte Benth, Kristin Klemmetsby Solli, Arild Opheim, Nikolaj Kunoe

JAMA Psychiatry· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
No increased pain among opioid-dependent individuals treated with extended-release naltrexone or buprenorphine-naloxone: A 3-month randomized study and 9-month open-treatment follow-up study.
Zill-E-Huma Latif, Kristin K Solli, Arild Opheim, Nikolaj Kunoe, Jūratė Š Benth

Am J Addict· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a 9-month follow-up to a 3-month randomized trial.
Kristin Klemmetsby Solli, Zill-E-Huma Latif, Arild Opheim, Peter Krajci, Kamni Sharma-Haase

Addiction· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial.
Lars Tanum, Kristin Klemmetsby Solli, Zill-E-Huma Latif, Jurate Šaltyte Benth, Arild Opheim

JAMA Psychiatry· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interest in Extended Release Naltrexone among Opioid Users.
Kamni Sharma Haase, Nikolaj Kunøe, Arild Opheim, Zhanna Gaulen, Anne-Lill Mjølhus Njå

Eur Addict Res· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX).
Nikolaj Kunøe, Arild Opheim, Kristin Klemmetsby Solli, Zhanna Gaulen, Kamni Sharma-Haase

BMC Pharmacol Toxicol· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis